Clinical trials: LOCALLY ADVANCED RECTAL CANCER
Rectal Cancer
Study of High-Dose-Rate Endorectal Brachytherapy (HDRBT) in the Treatment of Locally Advanced Low Rectal Cancer
This research is being done to see how effective high-dose rate endorectal brachytherapy (HDRBT) is in treating cancer of the lowest part of the bowel (rectum).
- Trial name
- HDRBT (NCT01226979)
- Testing
- High-dose endorectal brachytherapy (HDRBT)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Rectal Cancer
Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)
Colorectal cancer is a common gastrointestinal tumor, with rising incidence in China. Rectal cancer accounts for nearly half of new cases, and many patients are diagnosed at a locally advanced stage.
- Trial name
- PUCRT (NCT06770270)
- Testing
- Pucotenlimab
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Locally Advanced Rectal Cancer
Neoadjuvant Triplet Chemotherapy Regimen in Patients With Locally Advanced Rectal Cancer
This study aims to investigate the feasibility, safety and efficacy of triplet regimen of neoadjuvant chemotherapy in patients with locally advanced rectal cancer
- Trial name
- NCT03443661
- Testing
- FOLFOXIRI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Aiping Zhou
Colorectal Cancer
Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers
Phase 2A study, assessing the antitumor activity and the safety profile of GM102, a new compound (monoclonal antibody), administered alone or in combination with chemotherapy in patients with locally advanced or metastatic…
- Trial name
- NCT03799731
- Testing
- GM102, Trifluridine/Tipiracil, GM102 expansion
- Where
- 5 sites in Belgium, Czechia
- Volunteers
- 65 people
- Sponsor
- GamaMabs Pharma
Melanoma, Urothelial Carcinoma
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Safety study of RC198 in Subjects with Solid Tumors.
- Conditions
- Melanoma, Urothelial Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT05867303
- Testing
- RC198 Injection
- Where
- 5 sites in Australia, China
- Volunteers
- 48 people
- Sponsor
- RemeGen Co., Ltd.
Rectal Cancer
Preoporative Bevacizumab, Radiation Therapy, and XELOX Chemotherapy for Locally Advanced Nonmetastatic Rectal Cancer
We presumed that the addition of a monoclonal antibody Bevacizumab into radiation therapy and combination chemotherapy could results in improved pathologic tumor regression grade (TRG) in locally advanced nonmetastatic rectal…
- Trial name
- NCT01818973
- Testing
- Xeloda, Oxaliplatin, Bevacizumab
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Rectal Cancer
Short-course Radiotherapy Followed by Consolidation Chemotherapy. 2021-001206-29
The aim of the ShorTrip trail is to evaluate the activity and the safety of total neoadjuvant strategy with FOLFOXIRI as consolidation therapy preceded by short-course radiotherapy and followed by surgery in LARC patients.
- Trial name
- ShorTrip (NCT05253846)
- Testing
- Irinotecan, Oxaliplatin, Lederfolin
- Where
- Italy
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Rectal Cancer, Adenocarcinoma
Intestinal Microbiome Modulation With Antibiotics in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Colorectal cancer is the second most common malignancy worldwide and one-third of these tumors are located in the rectum. The treatment may involve up to three modalities: radiotherapy, chemotherapy, and surgery.
- Trial name
- NCT06793137
- Testing
- Metronidazole
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- AC Camargo Cancer Center
Neoplasm Malignant, Renal Cell Carcinoma
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This is a Phase 1, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect on biomarkers of XL092 administered alone, in combination…
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer
- Trial name
- STELLAR-001 (NCT03845166)
- Testing
- XL092, Atezolizumab, Avelumab
- Where
- 86 sites in United States, Australia and 8 more
- Volunteers
- 325 people
- Sponsor
- Exelixis
Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment
Total Neoadjuvant Chemoradiotherapy Plus Anti-PD-1 in Subperitoneal Patients With Locally Advanced Rectal CancerPatients With Locally Advanced Rectal Cancer: A Prospective, Single Arm, Exploratory Study
Previously, preliminary results, from a subgroup analysis of STARS-RC03 (NCT04906044) conducted by our research team, showed that the 6-cycles consolidation chemotherapy combining with anti-PD-1 therapy had a better tumor…
- Conditions
- Locally Advanced Rectal Cancer, Total Neoadjuvant Treatment, Anti-PD-1
- Trial name
- NCT05998122
- Testing
- nCRT → (CapeOX+Sintilimab)×6 → Surgery/W&W
- Where
- China
- Volunteers
- 45 people
- Sponsor
- The First Hospital of Jilin University
Rectal Cancer
Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
Preoperative chemoradiation leads to increased pelvic control and overall survival, but both distant and local disease control remain problematic in locally advanced rectal cancer patients.
- Trial name
- NCT00113230
- Testing
- Avastin (Bevacizumab, RHUMAB VEGF), Capecitabine, Radiation Therapy
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer, Advanced Solid Tumors Harboring the KRAS G12C Mutation
Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments
The purpose of this study is to allow continued access to opnurasib (JDQ443) to participants who are benefitting from treatment with opnurasib as a single agent or in combination with other study treatments in pre-defined…
- Trial name
- KontRASt-R (NCT07468071)
- Testing
- Opnurasib, TNO155, trametinib
- Where
- 21 sites in Belgium, Canada and 8 more
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
the Prognostic Value of Pre-treatment NLR in Patients With Locally Advenced Rectal Cancer and Post-treatment
The Prognostic Impact Of The Neutrophil To Lymphocyte Ratio In Patients With Locally Advanced Rectal Cancer
In this study, we aim to investigate the prognostic value of pre-treatment NLR in patients with locally advenced rectal cancer and post-treatment
- Trial name
- NCT05673343
- Volunteers
- 100 people
- Sponsor
- Assiut University
Rectal Cancer, Radiotherapy
Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC
This prospective, randomized phase II trial is designed to evaluate whether low-dose short-course radiotherapy differs from common-dose short-course radiotherapy in terms of efficacy when both regimens are sequentially combined…
- Trial name
- PRIDE-02 (NCT07646639)
- Testing
- Sintilimab + IL-2 Combined with CAPOX, Short-course low-dose radiotherapy, Short-course standard-dose radiotherapy
- Where
- China
- Volunteers
- 122 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Rectal Cancer Stage III
Neoadjuvant Chemotherapy Combined With Cetuximab for EGFR Wild Type Locally Advanced Rectal Cancer
A number of pilot studies had shown high rate of complete resection after neoadjuvant chemotherapy alone for local advanced rectal cancer(LARC), but they did not increase the ratio of pathological complete response (pCR) which…
- Trial name
- NCT03391843
- Testing
- FOLFOXIRI+Cetuximab regimen
- Where
- China
- Volunteers
- 100 people
- Sponsor
- RenJi Hospital
Neoplasms, Rectal
A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer
This study is conducted in adults with rectal cancer that has a certain genetic type. The main goal is to find out whether a longer treatment period with dostarlimab can help more participants have a complete response to…
- Trial name
- DuraSTAR (NCT07740720)
- Testing
- Dostarlimab
- Volunteers
- 90 people
- Sponsor
- GlaxoSmithKline
Melanoma and Metastatic Colorectal Cancer
A Phase I Study of Oral LGX818 in Adult Patients With Advanced or Metastatic BRAF Mutant Melanoma
CLGX818X2101 is a first-time in-human, phase I study to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of daily administered LGX818 (daily, twice daily and/or every-other-day), a RAF kinase…
- Trial name
- NCT01436656
- Testing
- LGX818
- Where
- 24 sites in United States, Australia and 5 more
- Volunteers
- 107 people
- Sponsor
- Pfizer
Colon Adenocarcinoma, ERBB2 Gene Amplification
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it…
- Conditions
- Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma
- Trial name
- NCT03365882
- Testing
- Cetuximab, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 798 sites in United States, Puerto Rico
- Volunteers
- 240 people
- Sponsor
- SWOG Cancer Research Network
Gastrointestinal Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05262491
- Testing
- BL-B01D1
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Patient Satisfaction, Quality of Life
Patient Experiences Following Urinary Diversion as Part of Surgery for Advanced and Recurrent Rectal Cancer
The outcomes of patients who undergo radical surgery for locally advanced and recurrent rectal cancer have improved vastly, but there is a lack of emphasis on the quality-of-life outcomes of these patients.
- Conditions
- Patient Satisfaction, Quality of Life, Patient Participation
- Trial name
- Pelvex 3 (NCT04715308)
- Testing
- Urinary diversion
- Where
- Ireland
- Volunteers
- 1,200 people
- Sponsor
- St Vincent's University Hospital, Ireland